Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide - Merck & Co

Drug Profile

Temozolomide - Merck & Co

Alternative Names: CCRG-81045; MB-39831; MK-7365; NSC-362856; RP-46161; SCH-52365; Temcad; Temodal; Temodar; Temomedac

Latest Information Update: 24 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MediciNova; Merck & Co; Schering-Plough; Stanford University; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Anaplastic astrocytoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Glioma; Malignant melanoma
  • Phase II Acute myeloid leukaemia
  • Phase I/II Glioblastoma
  • Phase I Gliosarcoma
  • No development reported Brain metastases; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer
  • Discontinued Non-Hodgkin's lymphoma; Prostate cancer; Sarcoma

Most Recent Events

  • 31 Dec 2018 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO) (NCT03782415)
  • 14 Sep 2018 Jonsson Comprehensive Cancer Center plans a phase II trial for Small cell lung cancer (Combination therapy, Recurrent, Second-line therapy or greater, Late-stage disease) in USA in October 2018 (PO) (NCT03672773)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top